Compare CENTA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENTA | VRDN |
|---|---|---|
| Founded | 1955 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 1996 | 2014 |
| Metric | CENTA | VRDN |
|---|---|---|
| Price | $37.84 | $22.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $36.75 | $35.46 |
| AVG Volume (30 Days) | 275.8K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.41 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $3,129,100,000.00 | $5,706,000.00 |
| Revenue This Year | $1.60 | $13.73 |
| Revenue Next Year | $2.04 | $279.00 |
| P/E Ratio | $13.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.97 | $13.18 |
| 52 Week High | $40.80 | $34.29 |
| Indicator | CENTA | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 62.73 |
| Support Level | $36.68 | $17.97 |
| Resistance Level | $40.20 | $34.18 |
| Average True Range (ATR) | 1.21 | 0.99 |
| MACD | -0.11 | 0.13 |
| Stochastic Oscillator | 23.25 | 67.40 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.